...
首页> 外文期刊>Journal of cardiovascular translational research. >Mesenchymal Stem Cell Exosomes in the Treatment of Myocardial Infarction: a Systematic Review of Preclinical In Vivo Studies
【24h】

Mesenchymal Stem Cell Exosomes in the Treatment of Myocardial Infarction: a Systematic Review of Preclinical In Vivo Studies

机译:间充质干细胞外泌体治疗心肌梗死:临床前体内研究的系统评价

获取原文
获取原文并翻译 | 示例

摘要

Several prior studies have highlighted the promise of mesenchymal stem cells (MSCs) as tools for treating myocardial infarction (MI) patients. While MSCs were initially thought to mediate post-MI repair through differentiation and replacement of injured cells, they are now thought to function by releasing exosomes carrying important cargos which can prevent apoptosis and facilitate revascularization in the context of MI. Herein, we comprehensively survey prior preclinical studies examining MSC-derived exosomes (MSC- Exos) utility for the repair of MI-related tissue injury. In total, 24 relevant studies were identified in the PubMed, Web of Science, Embase, and Cochrane Library databases as per the PRISMA guidelines. In most studies, exosome-treated rodents exhibited improved cardiac function and angiogenesis together with decreased apoptotic cell death. MSC-Exos thus offer beneficial therapeutic efficacy when treating MI injury. However, further work will be necessary to standardize experimental preclinical models and to validate these results.
机译:先前的几项研究强调了间充质干细胞 (MSC) 作为治疗心肌梗死 (MI) 患者的工具的前景。虽然间充质干细胞最初被认为通过分化和替换受损细胞来介导心肌梗死后修复,但现在人们认为它们通过释放携带重要货物的外泌体来发挥作用,这些外泌体可以防止细胞凋亡并促进心肌梗死背景下的血运重建。 在此,我们全面调查了先前的临床前研究,这些研究检查了MSC衍生的外泌体(MSC-Exos)在修复心肌梗死相关组织损伤方面的效用。根据PRISMA指南,在PubMed、Web of Science、Embase和Cochrane Library数据库中共确定了24项相关研究。在大多数研究中,外泌体处理的啮齿动物表现出改善的心脏功能和血管生成,同时减少凋亡细胞死亡。因此,MSC-Exos在治疗心肌梗死损伤时具有有益的治疗效果。然而,还需要进一步的工作来标准化实验性临床前模型并验证这些结果。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号